More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$499715849
EPS
-1.17
P/E ratio
--
Price to sales
5.4
Dividend yield
--
Beta
2.038377
Previous close
$15.22
Today's open
$15.31
Day's range
$15.06 - $16.27
52 week range
$3.22 - $18.43
show more
CEO
Cary Vance
Employees
226
Headquarters
Valencia, CA
Exchange
NASDAQ Capital Market
Shares outstanding
31687752
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes
Complete Cohealyx I data show earlier graft readiness, healing and improved scar scores through six months with no product-related adverse events reported
GlobeNewsWire • Nov 16, 2026

AVITA Medical Shares Rose 329% In A Year, Medicare Resets Its Billing Codes Next
AVITA Medical is rated Buy with a $20 twelve-month target, driven by a Medicare reimbursement reset effective January 1. RCEL's RECELL system, accounting for 86% of revenue, benefits most from nationalized Medicare rates, alleviating prior payment uncertainty and supporting continued growth. Despite a fourfold rally and premium 5.5x sales valuation, RCEL's robust 53% revenue growth, 84% gross margin, and improving cash flow justify scaling in before and after Q4 earnings.
Seeking Alpha • Nov 14, 2026

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. ( RCEL ) Shareholder/Analyst Call November 11, 2026 5:00 PM EST Company Participants Cary Vance - President, CEO & Executive Director David OToole - Chief Financial Officer Ben Atkins - Vice President of Investor Relations & Corporate Communications Conference Call Participants Rudi Michelson Presentation Rudi Michelson Good morning, and thank you for joining AVITA Medical quarterly Australian webinar. I'm Rudi Michelson of Monsoon Communications.
Seeking Alpha • Nov 12, 2026

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Nov 11, 2026

AVITA Medical, Inc. (RCEL) Q3 2026 Earnings Call Transcript
AVITA Medical, Inc. ( RCEL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - President, CEO & Executive Director David OToole - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Joshua Jennings - TD Cowen, Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 10, 2026

AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Nov. 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President & Chief Executive Officer, and David O'Toole, Chief Financial Officer, on Wednesday, November 11, 2026, at 2:00 p.m.
GlobeNewsWire • Nov 8, 2026

Avita Medical Q3 Earnings Call Highlights
Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.
MarketBeat • Nov 6, 2026

AVITA Medical Reports Third Quarter Results
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule.
GlobeNewsWire • Nov 5, 2026

AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026.
GlobeNewsWire • Oct 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Avita Medical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.